胰高血糖素样肽-1受体激动剂对糖尿病心肌病的影响  

Effect of Glucagon-Like Peptide-1 Receptor Agonist on Diabetic Cardiomyopathy

作　　者：林佳音 王莉莉[1] 于小晴 LIN Jiayin;WANG Lili;YU Xiaoqing(Department of Cardiology,The Second Hospital of Dalian Medical University,Dalian 116000,Liaoning,China)

机构地区：[1]大连医科大学附属第二医院心内科,辽宁大连116000

出　　处：《心血管病学进展》2023年第11期1024-1027,共4页Advances in Cardiovascular Diseases

摘　　要：随着糖尿病患病率逐年升高,糖尿病心肌病(DCM)的患病率也呈升高趋势。DCM初期的主要表现是心肌舒张及收缩功能障碍,最终导致临床心力衰竭。DCM的发病机制复杂多样,尚需进一步临床研究。近年来,胰高血糖素样肽-1受体激动剂在临床上得到广泛应用,其在降糖作用外兼具调节多种心血管危险因素,从而抑制动脉粥样硬化进程,减少冠状动脉事件,降低心血管死亡的发生率。然而胰高血糖素样肽-1受体激动剂对DCM的影响尚不明确,现就相关领域研究进行综述。As the prevalence of diabetes increases year by year,the prevalence of diabetic cardiomyopathy(DCM)is also increasing.The main manifestation of DCM in the early stage is myocardial diastolic and systolic dysfunction,which ultimately leads to clinical heart failure.Its pathogenesis is complex and multiple,and further clinical research is needed.In recent years,glucagon-like peptide-1(GLP-1)receptor agonist has been widely used in clinical practice.In addition to the hypoglycemic effect,it also regulates a variety of cardiovascular risk factors,thereby inhibiting the process of atherosclerosis,reducing coronary events,and reducing the incidence of cardiovascular death.However,the effect of GLP-1 receptor agonist on DCM is still unclear.This article reviews the research in related fields.

关 键 词：糖尿病心肌病 胰高血糖素样肽-1受体激动剂 氧化应激 

分 类 号：R587.2[医药卫生—内分泌] R542.2[医药卫生—内科学]